Changes in Body Composition Secondary to Neoadjuvant Chemotherapy for Advanced Esophageal Cancer are Related to the Occurrence of Postoperative Complications After Esophagectomy

Annals of Surgical Oncology

Volumn 21, Issue 11, 2014, Pages 3675-3679

  Ida, Satoshi ^a   Watanabe, Masayuki ^a   Karashima, Ryuichi ^a   Imamura, Yu ^a   Ishimoto, Takatsugu ^a   Baba, Yoshifumi ^a   Iwagami, Shiro ^a   Sakamoto, Yasuo ^a   Miyamoto, Yuji ^a   Yoshida, Naoya ^a   Baba, Hideo ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL; MINERAL; PROTEIN; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; ADVANCED CANCER; ADVANCED ESOPHAGEAL CANCER; ANASTOMOSIS LEAKAGE; ARTICLE; BODY COMPOSITION; BODY MASS; BODY WEIGHT; BONE MINERAL; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; FAT FREE MASS; FAT MASS; FEMALE; HUMAN; MALE; POSTOPERATIVE COMPLICATION; SKELETAL MUSCLE; SURGICAL INFECTION; TOTAL BODY WATER; TREATMENT DURATION; TUMOR LOCALIZATION; ADJUVANT THERAPY; ADVERSE EFFECTS; AGED; CARCINOMA, SQUAMOUS CELL; COMPLICATION; DRUG EFFECTS; ESOPHAGEAL NEOPLASMS; FOLLOW UP; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY COMPOSITION; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; SURVIVAL RATE; TAXOIDS;

EID: 84932162835     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-3737-z     Document Type: Article

References (22)

1. Earlam R, Cunha-Melo JR. Oesophageal squamous cell carcinoma: I. A critical review of surgery. Br J Surg. 1980;67:381–90.
2. Wu PC, Posner MC. The role of surgery in the management of oesophageal cancer. Lancet Oncol. 2003;4:481–8.
3. Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12:681–92.
4. Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19:68–74.
5. Hirao M, Ando N, Tsujinaka T, et al. Influence of preoperative chemotherapy for advanced thoracic oesophageal squamous cell carcinoma on perioperative complications. Br J Surg. 2011;98:1735–41.
6. Watanabe M, Nagai Y, Kinoshita K, et al. Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil for patients with node-positive esophageal cancer. Digestion. 2011;83:146–52.
7. Yoshida N, Watanabe M, Baba Y, et al. Influence of preoperative docetaxel, cisplatin, and 5-fluorouracil on the incidence of complications after esophagectomy for resectable advanced esophageal cancer. Dis Esophagus. 2014;27:374–9.
8. Jaffrin MY, Morel H. Body fluid volumes measurements by impedance: a review of bioimpedance spectroscopy (BIS) and bioimpedance analysis (BIA) methods. Med Eng Phys. 2008;30:1257–69.
9. Kim M, Kim H. Accuracy of segmental multi-frequency bioelectrical impedance analysis for assessing whole-body and appendicular fat mass and lean soft tissue mass in frail women aged 75 years and older. Eur J Clin Nutr. 2013;67:395–400.
10. Kaido T, Mori A, Ogura Y, et al. Pre- and perioperative factors affecting infection after living donor liver transplantation. Nutrition. 2012;28:1104–8.
11. Sobin LH, Gospodarowicz MK, Wittekind CW. TNM classification of malignant tumours. 7th ed. New York: Wiley-Blackwell; 2009.
12. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.
13. Grotenhuis BA, Wijnhoven BP, Grune F, van Bommel J, Tilanus HW, van Lanschot JJ. Preoperative risk assessment and prevention of complications in patients with esophageal cancer. J Surg Oncol. 2010;101:270–8.
14. Nozoe T, Kimura Y, Ishida M, Saeki H, Korenaga D, Sugimachi K. Correlation of pre-operative nutritional condition with post-operative complications in surgical treatment for oesophageal carcinoma. Eur J Surg Oncol. 2002;28:396–400.
15. Ryan AM, Reynolds JV, Healy L, et al. Enteral nutrition enriched with eicosapentaenoic acid (EPA) preserves lean body mass following esophageal cancer surgery: results of a double-blinded randomized controlled trial. Ann Surg. 2009;249:355–63.
16. Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med. 1980;69:491–7.
17. Han-Geurts IJ, Hop WC, Tran TC, Tilanus HW. Nutritional status as a risk factor in esophageal surgery. Dig Surg. 2006;23:159–63.
18. Chen Z, Wang Z, Lohman T, et al. Dual-energy X-ray absorptiometry is a valid tool for assessing skeletal muscle mass in older women. J Nutr. 2007;137:2775–80.
19. Jackson W, Alexander N, Schipper M, Fig L, Feng F, Jolly S. Characterization of changes in total body composition for patients with head and neck cancer undergoing chemoradiotherapy using dual-energy X-ray absorptiometry (DEXA). Head Neck. 2013. doi:10.1002/hed.23461.
20. Hennessey DB, Burke JP, Ni-Dhonochu T, Shields C, Winter DC, Mealy K. Preoperative hypoalbuminemia is an independent risk factor for the development of surgical site infection following gastrointestinal surgery: a multi-institutional study. Ann Surg. 2010;252:325–9.
21. Kawaguchi T, Taniguchi E, Itou M, et al. Body cell mass is a useful parameter for assessing malnutrition and severity of disease in non-ascitic cirrhotic patients with hepatocellular carcinoma or esophageal varices. Int J Mol Med. 2008;22:589–94.
22. Peng PD, van Vledder MG, Tsai S, et al. Sarcopenia negatively impacts short-term outcomes in patients undergoing hepatic resection for colorectal liver metastasis. HPB (Oxford). 2011;13:439–46.